Market Overview - The net inflow of main funds in the Shanghai and Shenzhen markets reached 27.724 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 3.374 billion yuan [1] - A total of 269 stocks experienced net inflows, while 320 stocks faced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 532 stocks rose, with four stocks hitting the daily limit, including Zhengyuan Dixin and Fangyuan Co., while 55 stocks declined [1] - Among the stocks with significant net inflows, 11 stocks had inflows exceeding 100 million yuan, with SMIC leading at 978 million yuan [2] Continuous Fund Flow - There are 27 stocks that have seen continuous net inflows for more than three trading days, with Kangwei Century leading at 13 consecutive days of inflow [2] - Conversely, 180 stocks have experienced continuous outflows, with Hangke Technology facing the longest streak at 14 consecutive days of outflow [2] Top Fund Inflows - The top stocks by net inflow include: - SMIC: 977.8 million yuan, with a flow rate of 9.89% and a price increase of 3.72% [2] - Haiguang Information: 457.1 million yuan, with a flow rate of 5.76% and a price increase of 3.57% [2] - Zhongwei Company: 308.7 million yuan, with a flow rate of 8.48% and a price increase of 2.61% [2] Notable Outflows - The stock with the highest net outflow is Huahong Company, which saw a net outflow of 287 million yuan and a price decrease of 0.62% [1] - Other notable outflows include Dongxin Co. and Jinghe Integration, with net outflows of 178 million yuan and 157 million yuan, respectively [1]

Core Viewpoint - As of October 16, a total of 106 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Notable Financing Inflows - The stock with the longest consecutive net inflow is Xingye Yinx, which has seen net buying for 13 consecutive trading days [1] - Other stocks with significant consecutive net inflows include Tongfang Co., Kangwei Century, Huaming Equipment, Huacan Optoelectronics, Guizhou Tire, Power Diamond, Yaxin Security, and Yuntianhua [1]

Core Viewpoint - 康为世纪 reported a significant increase in revenue for the first half of 2025, but continued to face net losses, indicating ongoing financial challenges despite growth in sales [1][2]. Financial Performance - The company achieved operating revenue of 87.12 million yuan in the first half of 2025, representing a year-on-year increase of 29.74% [1][2]. - The net profit attributable to shareholders was -55.91 million yuan, compared to -50.06 million yuan in the same period last year, reflecting an increase in losses of 11.70% [1][2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -66.56 million yuan, compared to -61.15 million yuan in the previous year, marking an 8.84% increase in losses [1][2]. - The net cash flow from operating activities was -49.66 million yuan, an improvement of 16.15% from -59.22 million yuan in the same period last year [1][2]. Historical Context - 康为世纪 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an issuance price of 48.98 yuan per share, raising a total of 1.14 billion yuan [3]. - The company’s net fundraising amount was 1.05 billion yuan after deducting issuance costs, exceeding the original plan by 68.63 million yuan [3]. - The funds raised are intended for projects related to medical devices, biological testing reagents, marketing network construction, and molecular detection product development [3]. Shareholder Actions - On June 6, 2023, 康为世纪 announced a dividend plan, distributing 5.2 yuan (pre-tax) for every 10 shares and a bonus issue of 2 shares [4].

Core Insights - As of October 15, a total of 122 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] Group 1: Stocks with Longest Continuous Net Inflows - The stocks with the longest continuous net inflows are Xingye Yinxin, Wancheng Group, and Zhongjin Gold, each having recorded net inflows for eight consecutive trading days [1] - Other notable stocks with significant net inflows include Huacan Optoelectronics, Tongfang Co., Yuntianhua, Haoneng Co., Taijing Technology, Guizhou Tire, and Kangwei Century [1]

二○二五年十月 江苏康为世纪生物科技股份有限公司 2025 年第二次临时股东会会议资料 目录 | 2025 | 年第二次临时股东会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东会会议议程 | 5 | | 2025 | 年第二次临时股东会会议议案 | 6 | | | 议案一《关于续聘公司 2025 年度财务审计机构及内控审计机构的议案》 | 6 | 2 / 6 江苏康为世纪生物科技股份有限公司 2025 年第二次临时股东会会议资料 江苏康为世纪生物科技股份有限公司 2025 年第二次临时股东会 会议资料 四、为保证会场秩序，进入会场后，请关闭手机或调至振动状态。谢绝个人 录音、拍照及录像。场内请勿大声喧哗。对干扰会议正常秩序、侵犯其他股东合 法权益的行为，工作人员有权予以制止，并及时报告有关部门查处。 五、股东参加股东会依法享有发言权、质询权、表决权等权利。股东要求在 股东会上发言或就相关问题提出质询的，应事先在股东会签到处进行登记。股东 不得无故中断会议议程要求发言。股东现场提问请举手示意，经会议主持人许可 方可发言。股东及股东代理人发言或提问应围绕本次会议议 ...

Core Insights - As of October 14, a total of 78 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest streak of net inflows is Daming City, which has seen net buying for 13 consecutive trading days [1] - Other notable stocks with significant net inflow days include Zhongjin Gold, Wancheng Group, Yuntianhua, Xujie Electric, Kangwei Century, Xingye Yinxin, Zhidi Technology, and Taijing Technology [1]

Core Viewpoint - The acquisition of 51% stake in Shanghai Haowei Technology by Kangwei Century for 12.75 million yuan is a strategic move to enhance its capabilities in the molecular diagnostics and multi-omics service sectors, marking a significant step towards fourth-generation gene sequencing technology and precision medical services [2][4][14] Transaction Details - The acquisition price is set at 12.75 million yuan, funded by the company's own resources, which will not significantly impact daily operations [3] - After the acquisition, Kangwei Century will hold 51% of Haowei Technology, while Tianhao Biotechnology retains 49% [3] Performance Targets and Risks - Haowei Technology is committed to achieving over 20% revenue growth in 2025; failure to meet this target may trigger a compensation mechanism for Kangwei Century [4] - Potential risks include uncertainties in agreement execution, increased management costs during integration, and changes in industry policies [4] Market Environment - The molecular diagnostics market in China has been growing rapidly, with a projected market size of 50 billion yuan in 2024 and expected to exceed 150 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of over 20% [5] - The multi-omics integration analysis market is expected to grow even faster, with a CAGR of 30% [5] - Domestic companies are gaining market share by offering lower prices and faster service delivery compared to international giants [5] Company Overview: Kangwei Century - Established in 2007, Kangwei Century specializes in molecular detection enzyme raw materials and diagnostic kits, with a strong focus on independent technology development [8] - The company has launched over 700 products, breaking international monopolies in several niche areas [8] - Kangwei Century is advancing towards fourth-generation nanopore sequencing technology, aiming for scalable production and application in both research and clinical settings [8] Company Overview: Haowei Technology - Founded in 2024, Haowei Technology focuses on microbiome detection, multi-omics analysis, and bioinformatics services, targeting research institutions and biopharmaceutical companies [9][10] - The company achieved 8 million yuan in revenue in 2024, with service accuracy exceeding 95% and a 30% reduction in service delivery time [10] Synergistic Effects - The acquisition is part of Kangwei Century's strategy of combining internal research and external acquisitions, aiming to enhance its service capabilities across various disease areas [11] Future Outlook - The acquisition positions Kangwei Century to enter the multi-omics research service market, strengthening its overall presence in the molecular diagnostics industry [14] - The company anticipates a 25% revenue growth and a net profit margin increase to 22% by 2025, driven by the rising demand for precision medicine [14] - The integration of multi-omics and fourth-generation sequencing technologies is expected to create a competitive edge for domestic companies against imported products [14]

Group 1: Company Announcements - Hezhong Intelligent (合锻智能) reported no revenue from nuclear fusion-related business [1] - Fostar (福斯达) plans to invest approximately 1 billion yuan in the construction of a marine engineering and equipment intelligent manufacturing project [1] - Zhongyan Dadi (中岩大地) won a contract for a 770 million yuan engineering project [1] - Meili Technology (美力科技) intends to acquire 10.1% equity in Beijing Dayuan and Jiangsu Dayuan [1] - Jiuan Medical (九安医疗) plans to repurchase shares worth 300 million to 600 million yuan [1] - Sanmei Co., Ltd. (三美股份) expects a net profit increase of 171.73% to 193.46% year-on-year for the first three quarters [1] - Chen Yategong (陈亚特工) plans to reduce holdings by 2.99% [1] - Asia-Pacific Pharmaceutical (亚太药业) intends to raise no more than 700 million yuan through a private placement to Xinghao Holdings [1] - Feiliwa (非利华) plans to raise no more than 300 million yuan through a private placement [2] Group 2: Investment Projects - New Asia Cable (新亚电缆) plans to invest 298 million yuan in a green and environmentally friendly cable industry project [1] - Fostar (福斯达) is set to invest about 1 billion yuan in a marine engineering and equipment intelligent manufacturing project [1] Group 3: Share Buybacks - China Merchants Industry Holdings (中远海控) plans to repurchase 50 million to 100 million A-shares [2] - Jiuan Medical (九安医疗) intends to repurchase shares worth 300 million to 600 million yuan [2] - China National Machinery Industry Corporation (中工国际) plans to repurchase shares worth 50 million to 100 million yuan [2] - Fujilai (富士莱) plans to repurchase shares worth 20 million to 40 million yuan [2] - Obizhongguang (奥比中光) plans to repurchase shares worth 25 million to 50 million yuan [2] Group 4: Performance Forecasts - Sanmei Co., Ltd. (三美股份) expects a net profit increase of 171.73% to 193.46% year-on-year for the first three quarters [2] - Yuegui Co., Ltd. (粤桂股份) anticipates a net profit increase of 86.87% to 109.11% year-on-year for the first three quarters [2] - Salt Lake Co., Ltd. (盐湖股份) expects a net profit increase of 36.89% to 49.62% year-on-year for the first three quarters [2] - Shengnuo Biotechnology (圣诺生物) anticipates a net profit increase of 100.53% to 145.1% year-on-year for the first three quarters [2] Group 5: Equity Transfers - Yonghe Zhikong (永和智控) plans to transfer 51% equity and debt of Taixing Puluo [1] - Meizhi Co., Ltd. (美芝股份) plans to transfer 51% equity of Yingju Construction [1] - Meili Technology (美力科技) intends to acquire 10.1% equity in Beijing Dayuan and Jiangsu Dayuan [1] - Kangwei Century (康为世纪) plans to acquire 49% equity of its subsidiary Haowei Tai [1]

Group 1 - The core transaction on October 13 involved a block trade of 159,100 shares of Kangwei Century, with a transaction value of 4.4739 million yuan, at a price of 28.12 yuan per share [2][3] - The buyer of the block trade was Shenwan Hongyuan Securities Co., Ltd. International Department, while the seller was Huatai Securities Co., Ltd. Shanghai Branch [2][3] - On the same day, Kangwei Century's closing price was 28.12 yuan, reflecting an increase of 1.48%, with a turnover rate of 3.31% and a total transaction amount of 34.8452 million yuan [2][3] Group 2 - The net inflow of main funds for Kangwei Century was 1.9631 million yuan, with a cumulative increase of 4.54% over the past five days, and a total net inflow of 9.8209 million yuan [2][3] - The latest margin financing balance for the stock is 116 million yuan, which has increased by 31.1083 million yuan, representing a growth of 36.49% over the past five days [3] - Jiangsu Kangwei Century Biotechnology Co., Ltd. was established on September 3, 2010, with a registered capital of 1,124.93716 million yuan [3]

Core Viewpoint - 康为世纪 plans to acquire the remaining 49% stake in its subsidiary, 上海昊为泰生物科技有限公司, for 17.885 million yuan, making it a wholly-owned subsidiary, which aims to enhance management control and improve overall profitability and competitiveness [1] Group 1: Acquisition Details - 康为世纪 currently holds a 51% stake in 昊为泰 and intends to purchase the remaining 49% from 上海天昊生物科技有限公司 [1] - The acquisition price is set at 17.885 million yuan [1] Group 2: Business Operations of 昊为泰 - 昊为泰's primary revenue comes from technology service income, including various testing services such as microbiome testing, multi-omics integration analysis, third-generation sequencing, single-cell sequencing, metabolomics, proteomics testing, and bioinformatics analysis [1] Group 3: Strategic Rationale - The acquisition aligns with 康为世纪's future strategic development plans and operational needs, aiming to strengthen control over 昊为泰 and enhance decision-making efficiency [1] - This move is expected to bolster the company's overall profitability and competitive edge in the market [1]